Fluoro-deoxy-glucose-(18f) Positron Emission Tomography in Diagnostic of Carcinoma of Unknown Origin
DOI:
https://doi.org/10.5457/ams.v40i2.214Keywords:
carcinoma of unknown origin, positron emission tomography, breast adenocarcinomaAbstract
Carcinoma of unknown origin is defined as the absence of primary tumor and biopsy proved the existence of metastatic changes. The incidence is about 3% of all cancers. We present a case of a patient who underwent surgery for left breast mammography verified pathological lymphonodes on the left breast and on the left axillary region. Histopathological analysis of excised tissue showed the absence of malignant disease in the breast. A complete diagnostic evaluation also did not confirm the primary lesion. We done fluorodeoxyglucosa positron emission tomography, which had set suspicion of primary breast cancer, but biopsy and pathological reverification were not confirmed. The patient spent six cycles of chemotherapy for cancer of unknown origin. After a year and six months because of sudden right side hemiparesis were performed Computed Tomography and Magnetic Resonance imaging of the head, which indicated that it was a metastatic brain tumour. After metastasectomy, histopathological finding was finally proved to be a metastasis of breast adenocarcinomas. The patient had irradiation of the cranium, and began chemotherapy protocol for breast cancer. In this case, insufficient diagnosis did not affect in the proper therapeutic approach.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
